Compile Data Set for Download or QSAR

Found 302 hits Enz. Inhib. hit(s) with all data for entry = 10350   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM416765 (1-(3-(aminomethyl)phenyl)-N-(3-(phenyl(propoxy)met...) Show SMILES CCCOC(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C28H27F3N4O2/c1-2-14-37-26(20-9-4-3-5-10-20)21-11-7-12-22(16-21)33-27(36)24-17-25(28(29,30)31)34-35(24)23-13-6-8-19(15-23)18-32/h3-13,15-17,26H,2,14,18,32H2,1H3,(H,33,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439372 (US10633345, Compound 95i | US10689346, Compound 95...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(cc(c1)C1CC1)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C32H32F3N5O/c33-32(34,35)29-17-28(40(39-29)27-8-4-5-21(13-27)18-36)31(41)38-26-15-24(22-11-12-22)14-25(16-26)30(37-19-20-9-10-20)23-6-2-1-3-7-23/h1-8,13-17,20,22,30,37H,9-12,18-19,36H2,(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416794 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416856 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1O)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-19(27(35-16-17-8-9-17)21-6-1-2-7-25(21)39)13-23(22)36-28(40)24-14-26(29(31,32)33)37-38(24)20-5-3-4-18(12-20)15-34/h1-7,10-14,17,27,35,39H,8-9,15-16,34H2,(H,36,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439407 (US10633345, Compound 52h | US10633345, Compound 71...) Show SMILES CN(C(c1ccc(cc1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1 Show InChI InChI=1S/C30H26F4N6O/c1-39(22-10-11-22)28(20-7-5-18(16-35)6-8-20)21-9-12-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-4-2-3-19(13-23)17-36/h2-9,12-15,22,28H,10-11,17,36H2,1H3,(H,37,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416853 (1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(N)c1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-23-10-9-20(27(40-16-17-7-8-17)19-4-2-5-21(35)12-19)13-24(23)36-28(39)25-14-26(29(31,32)33)37-38(25)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27H,7-8,15-16,34-35H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416874 (1-(3-(aminomethyl)phenyl)-N-(3-(((1-hydroxybutan-2...) Show SMILES CCC(CO)NC(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C29H30F3N5O2/c1-2-22(18-38)34-27(20-9-4-3-5-10-20)21-11-7-12-23(15-21)35-28(39)25-16-26(29(30,31)32)36-37(25)24-13-6-8-19(14-24)17-33/h3-16,22,27,34,38H,2,17-18,33H2,1H3,(H,35,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM447737 (US10689346, Compound 250c | US11203574, Compound 2...) Show SMILES Fc1ccc(cc1NC(=O)c1cc(nn1-c1cccc(c1)C#N)C(F)(F)F)C(CCC1CC1)Oc1ccccn1 Show InChI InChI=1S/C29H23F4N5O2/c30-22-11-10-20(25(12-9-18-7-8-18)40-27-6-1-2-13-35-27)15-23(22)36-28(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,25H,7-9,12H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416794 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416957 ((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cycloprop...) Show SMILES CS(=O)(=O)NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2ccc3ccnc(N)c3c2)C(F)(F)F)c1 Show InChI InChI=1S/C32H29F4N7O3S/c1-47(45,46)42-31(12-8-19-2-3-19,21-10-13-38-14-11-21)22-5-7-25(33)26(16-22)40-30(44)27-18-28(32(34,35)36)41-43(27)23-6-4-20-9-15-39-29(37)24(20)17-23/h4-7,9-11,13-19,42H,2-3,8,12H2,1H3,(H2,37,39)(H,40,44)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417006 ((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N)C(F)(F)F Show InChI InChI=1S/C31H27F4N7O/c32-24-10-9-22(30(39,12-11-18-7-8-18)21-5-1-3-19(13-21)17-36)15-25(24)40-29(43)26-16-27(31(33,34)35)41-42(26)23-6-2-4-20(14-23)28(37)38/h1-6,9-10,13-16,18H,7-8,11-12,39H2,(H3,37,38)(H,40,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417012 ((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F Show InChI InChI=1S/C31H27F4N7O/c32-24-11-10-22(30(39,13-12-18-4-5-18)21-8-6-19(17-36)7-9-21)15-25(24)40-29(43)26-16-27(31(33,34)35)41-42(26)23-3-1-2-20(14-23)28(37)38/h1-3,6-11,14-16,18H,4-5,12-13,39H2,(H3,37,38)(H,40,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417018 ((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N7O/c30-22-9-8-19(28(36,11-10-17-6-7-17)20-4-2-12-37-16-20)14-23(22)38-27(41)24-15-25(29(31,32)33)39-40(24)21-5-1-3-18(13-21)26(34)35/h1-5,8-9,12-17H,6-7,10-11,36H2,(H3,34,35)(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417024 ((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C29H28F4N6O/c30-23-7-6-21(28(35,11-8-18-4-5-18)20-9-12-36-13-10-20)15-24(23)37-27(40)25-16-26(29(31,32)33)38-39(25)22-3-1-2-19(14-22)17-34/h1-3,6-7,9-10,12-16,18H,4-5,8,11,17,34-35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416718 (1-(3-(aminomethyl)phenyl)-N-(2-fluoro-5-(phenyl(pr...) Show SMILES CCCN(c1ccccc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C27H25F4N5O/c1-2-13-35(19-8-4-3-5-9-19)20-11-12-22(28)23(15-20)33-26(37)24-16-25(27(29,30)31)34-36(24)21-10-6-7-18(14-21)17-32/h3-12,14-16H,2,13,17,32H2,1H3,(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416720 (1-(3-(aminomethyl)phenyl)-N-(2-fluoro-3-(phenyl(pr...) Show SMILES CCCN(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1F Show InChI InChI=1S/C27H25F4N5O/c1-2-14-35(19-9-4-3-5-10-19)22-13-7-12-21(25(22)28)33-26(37)23-16-24(27(29,30)31)34-36(23)20-11-6-8-18(15-20)17-32/h3-13,15-16H,2,14,17,32H2,1H3,(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416721 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-15-24(36(35-25)22-8-3-5-19(13-22)16-32)27(37)34-21-7-4-6-20(14-21)26(38-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26H,10-11,16-17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416730 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-ph...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O/c31-30(32,33)28-18-27(37(36-28)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)26(15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,26H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416733 (1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-14-24(37(36-25)23-8-1-4-19(12-23)15-32)27(38)35-22-7-2-5-20(13-22)26(34-16-18-9-10-18)21-6-3-11-33-17-21/h1-8,11-14,17-18,26,34H,9-10,15-16,32H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416736 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(F)cc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H26F4N4O2/c30-22-12-21(27(39-17-18-9-10-18)20-6-2-1-3-7-20)13-23(14-22)35-28(38)25-15-26(29(31,32)33)36-37(25)24-8-4-5-19(11-24)16-34/h1-8,11-15,18,27H,9-10,16-17,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416739 (1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropylethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)N(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)27-18-26(37(35-27)25-11-4-6-21(16-25)19-33)28(38)34-22-7-5-10-24(17-22)36(15-14-20-12-13-20)23-8-2-1-3-9-23/h1-11,16-18,20H,12-15,19,33H2,(H,34,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416742 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(NCC2CC2)c2ccccc2)c1F)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-26-22(27(35-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)36-28(39)24-15-25(29(31,32)33)37-38(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27,35H,12-13,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416745 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1nccs1)C(F)(F)F Show InChI InChI=1S/C26H24F3N5O2S/c27-26(28,29)22-13-21(34(33-22)20-6-1-3-17(11-20)14-30)24(35)32-19-5-2-4-18(12-19)23(25-31-9-10-37-25)36-15-16-7-8-16/h1-6,9-13,16,23H,7-8,14-15,30H2,(H,32,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416747 (1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H26F4N4O2/c30-23-12-11-21(27(39-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)35-28(38)25-15-26(29(31,32)33)36-37(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27H,9-10,16-17,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416748 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)22-8-3-5-19(13-22)16-32)27(38)35-21-7-4-6-20(14-21)26(34-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26,34H,10-11,16-17,32H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416757 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(1...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)n1ccnc1)C(F)(F)F Show InChI InChI=1S/C27H27F3N6O/c28-27(29,30)25-15-24(36(34-25)22-6-1-3-19(13-22)16-31)26(37)33-21-5-2-4-20(14-21)23(10-9-18-7-8-18)35-12-11-32-17-35/h1-6,11-15,17-18,23H,7-10,16,31H2,(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416760 ((E/Z)-1-(3-(Aminomethyl)phenyl)-N-(3-(3-cyclopropy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(=C\CC1CC1)\c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H27F3N4O/c31-30(32,33)28-18-27(37(36-28)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)26(15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,15-18,20H,12-14,19,34H2,(H,35,38)/b26-15+	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439347 (US10633345, Compound 41e | US10689346, Compound 41...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)26-16-25(37(36-26)24-11-4-6-20(14-24)17-33)28(38)35-23-10-5-9-22(15-23)27(34-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27,34H,12-13,17-18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416764 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)23-6-1-3-19(13-23)16-32)27(38)35-22-5-2-4-21(14-22)26(34-17-18-7-8-18)20-9-11-33-12-10-20/h1-6,9-15,18,26,34H,7-8,16-17,32H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416766 (1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropyletho...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)28(22-7-2-1-3-8-22)39-15-14-20-12-13-20/h1-11,16-18,20,28H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416767 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-24(37(36-26)23-8-3-5-20(15-23)18-33)27(38)35-22-7-4-6-21(16-22)28(39,13-12-19-10-11-19)25-9-1-2-14-34-25/h1-9,14-17,19,39H,10-13,18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416774 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-25(37(36-26)24-6-1-3-20(15-24)18-33)27(38)35-23-5-2-4-22(16-23)28(39,12-9-19-7-8-19)21-10-13-34-14-11-21/h1-6,10-11,13-17,19,39H,7-9,12,18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416777 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cn[nH]c1)C(F)(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416779 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(OCC2CC2)c2ccccc2)c1F)C(F)(F)F Show InChI InChI=1S/C29H26F4N4O2/c30-26-22(27(39-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)35-28(38)24-15-25(29(31,32)33)36-37(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27H,12-13,16-17,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416780 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1nccs1)C(F)(F)F Show InChI InChI=1S/C26H25F3N6OS/c27-26(28,29)22-13-21(35(34-22)20-6-1-3-17(11-20)14-30)24(36)33-19-5-2-4-18(12-19)23(25-31-9-10-37-25)32-15-16-7-8-16/h1-6,9-13,16,23,32H,7-8,14-15,30H2,(H,33,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416782 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES COc1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O2/c1-40-25-10-4-7-22(15-25)28(35-18-19-11-12-19)21-6-3-8-23(14-21)36-29(39)26-16-27(30(31,32)33)37-38(26)24-9-2-5-20(13-24)17-34/h2-10,13-16,19,28,35H,11-12,17-18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416783 (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc2ccccc2c1)C(F)(F)F Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)28-10-3-5-22(15-28)19-37)32(42)39-27-9-4-8-25(17-27)31(38-20-21-11-12-21)26-14-13-23-6-1-2-7-24(23)16-26/h1-10,13-18,21,31,38H,11-12,19-20,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416784 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F4N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416785 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES Cc1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O/c1-19-5-2-7-22(13-19)28(35-18-20-11-12-20)23-8-4-9-24(15-23)36-29(39)26-16-27(30(31,32)33)37-38(26)25-10-3-6-21(14-25)17-34/h2-10,13-16,20,28,35H,11-12,17-18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416786 (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc2ccccc12)C(F)(F)F Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)26-11-3-6-22(16-26)19-37)32(42)39-25-10-4-9-24(17-25)31(38-20-21-14-15-21)28-13-5-8-23-7-1-2-12-27(23)28/h1-13,16-18,21,31,38H,14-15,19-20,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416788 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(c1)C(F)(F)F)C(F)(F)F Show InChI InChI=1S/C30H27F6N5O/c31-29(32,33)22-7-2-5-20(13-22)27(38-17-18-10-11-18)21-6-3-8-23(14-21)39-28(42)25-15-26(30(34,35)36)40-41(25)24-9-1-4-19(12-24)16-37/h1-9,12-15,18,27,38H,10-11,16-17,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F Show InChI InChI=1S/C29H28F4N6O/c30-23-11-8-20(27(36-16-17-4-5-17)19-6-9-21(35)10-7-19)13-24(23)37-28(40)25-14-26(29(31,32)33)38-39(25)22-3-1-2-18(12-22)15-34/h1-3,6-14,17,27,36H,4-5,15-16,34-35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416790 (1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1Cl)C(NCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26ClF3N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416791 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(cc1)S(N)(=O)=O)C(F)(F)F Show InChI InChI=1S/C29H29F3N6O3S/c30-29(31,32)26-15-25(38(37-26)23-6-1-3-19(13-23)16-33)28(39)36-22-5-2-4-21(14-22)27(35-17-18-7-8-18)20-9-11-24(12-10-20)42(34,40)41/h1-6,9-15,18,27,35H,7-8,16-17,33H2,(H,36,39)(H2,34,40,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>

Jump to: